Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus P-HDFL in advanced gastric cancer
NCT00275951Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Dec 2005
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in gastric cancer (GC), sponsored by National Taiwan University Hospital. Primary endpoint: Objective Response Rate at 4 weeks. Started Dec 2005; status: completed.
02
Drugs
KL-140
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00275951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275951.